Home › Companies › BICYCLE THERAPEUTICS PLC › 2024-2025

BICYCLE THERAPEUTICS PLC 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and BICYCLE THERAPEUTICS PLC’s Form 8-K, filed 2025-06-17 (Item 5.07 on EDGAR). Page generated 02 October 2026.

9Reported items
108Asset managers
364Fund votes
2025-06-17Meeting date

Proxy season: 2023-2024 2024-2025

Explore BICYCLE THERAPEUTICS PLC in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BICYCLE THERAPEUTICS PLC

These tallies are BICYCLE THERAPEUTICS PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BICYCLE THERAPEUTICS PLC — official shareholder meeting results, meeting held 2025-06-17
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 1: To re-elect as a director Alessandro Riva.	40,034,345	9,086,349	14,365	14,365	--	Majority: yes
Proposal 2: To re-elect as a director Stephen Sands.	47,652,747	1,481,237	1,075	1,075	--	Majority: yes
Proposal 3: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement.	47,287,428	1,743,008	104,623	104,623	--	Majority: yes
Proposal 4: To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.S	49,093,195	41,363	501	501	--	Majority: yes
Proposal 5: To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.K	49,094,477	40,022	560	560	--	Majority: yes
Proposal 6: To authorize the Audit Committee of the Company's Board of Directors (the "Board") to determine the Company's U.K	49,116,858	17,701	500	500	--	Majority: yes
Proposal 7: To receive and adopt the Company's U.K	49,001,464	133,090	505	505	--	Majority: yes
Proposal 8: To approve the directors' remuneration report for the year ended December 31, 2024, which report is set forth in the Company's definitive proxy statement.	47,393,255	1,733,604	8,200	8,200	--	Majority: yes
Proposal 9: To approve an amendment to the Company's Amended and Restated 2020 Equity Incentive Plan, which amendment is set forth in the Company's definitive proxy statement.	38,137,068	10,979,123	18,868	18,868	--	Majority: yes

Source: BICYCLE THERAPEUTICS PLC, Form 8-K, filed with the SEC on 2025-06-17 — read the filing on EDGAR.

How asset managers voted at the BICYCLE THERAPEUTICS PLC 2024-2025 meeting

Each item below shows how the 108 asset managers that disclosed a BICYCLE THERAPEUTICS PLC vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BICYCLE THERAPEUTICS PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 47,287,428AGAINST: 1,743,008

BICYCLE THERAPEUTICS PLC’s own tally for this item (“Proposal 3: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement.”): 47,287,428 for, 1,743,008 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,202,355 outstanding shares: 68% for, 3% against (71% of the company cast a for/against vote).

The 106 asset managers below cast 95% of the shares they voted on this item FOR (32,027,810 for, 1,609,154 against).

FOR 95%

FOR: 32,027,810 (95.2%)AGAINST: 1,609,154 (4.8%)

Largest asset managers voting on “TO APPROVE, ON ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STA” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Against	Vote
BAKER BROS. ADVISORS LP	10,885,357	0	For
FCPM III SERVICES B.V.	3,452,330	0	For
Point72	3,296,624	0	For
T. Rowe Price	2,760,298	0	For
ARMISTICE CAPITAL, LLC	2,162,468	0	For
WESTFIELD CAPITAL MANAGEMENT CO LP	2,113,223	0	For
Siren, L.L.C.	1,552,106	0	For
BNP Paribas Asset Management Holding S.A.	0	1,054,752	Against
HARBOR FUNDS	1,000,820	0	For
EcoR1 Capital, LLC	910,000	0	For
AXA INVESTMENT MANAGERS UK Ltd	0	553,682	Against
Deep Track Capital, LP	485,355	0	For
PRINCIPAL GLOBAL INVESTORS	408,296	0	For
Woodline Partners LP	362,325	0	For
COMERICA BANK	306,779	0	For
Principal	293,300	0	For
PLATINUM INVESTMENT MANAGEMENT LTD	287,599	0	For
BlackRock	167,013	0	For
Harbor Funds II	149,250	0	For
SILVERCREST ASSET MANAGEMENT GROUP LLC	134,059	0	For
Renaissance	121,660	0	For
PINNACLE ASSOCIATES LTD	106,155	0	For
Janney Montgomery Scott LLC	105,978	0	For
Goldman Sachs	101,403	0	For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	83,741	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

2. TO APPROVE OUR DIRECTORS' REMUNERATION REPORT FOR THE YEAR ENDED DECEMBER 31, 2024 (THE "DIRECTORS' REMUNERATION REPORT"), WHICH IS SET FORTH AS ANNEX A TO THE PROXY STATEMENT.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 47,393,255AGAINST: 1,733,604

BICYCLE THERAPEUTICS PLC’s own tally for this item (“Proposal 8: To approve the directors' remuneration report for the year ended December 31, 2024, which report is set forth in the Company's definitive proxy statement.”): 47,393,255 for, 1,733,604 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,202,355 outstanding shares: 68% for, 3% against (71% of the company cast a for/against vote).

The 31 asset managers below cast 100% of the shares they voted on this item FOR (5,012,466 for, 0 against).

FOR 100%

FOR: 5,012,466 (100.0%)

Largest asset managers voting on “TO APPROVE OUR DIRECTORS' REMUNERATION REPORT FOR THE YEAR ENDED DECEMBER 31, 2024 (THE "DIRECTORS' REMUNERATI” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Vote
Siren, L.L.C.	1,552,106	For
T. Rowe Price	1,231,314	For
HARBOR FUNDS	1,000,820	For
Principal	293,300	For
Palo Alto Investors LP	248,934	For
BlackRock	167,013	For
Harbor Funds II	149,250	For
Goldman Sachs	100,250	For
Morgan Stanley	58,724	For
State Street	31,423	For
John Hancock	25,602	For
OLD WESTBURY FUNDS INC	25,352	For
WOODSTOCK CORP	24,981	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	21,900	For
Harbor ETF Trust	16,482	For
Listed Funds Trust	14,396	For
ETF Series Solutions	12,764	For
STEWARD FUNDS, INC.	11,209	For
Equitable	11,014	For
Mercer Funds	5,511	For
ETFis Series Trust I	4,131	For
ProShares	1,779	For
Argent Trust Co	1,690	For
ADVISOR PARTNERS II, LLC	1,173	For
Granahan Investment Management, LLC	404	For

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

3. To approve an amendment to our Amended and Restated 2020 Equity Incentive Plan, which amendment is set forth as Annex C to the proxy statement.

COMPENSATIONMajority of the votes cast: yes

78% Majority: yes · of votes cast

FOR 78%AGAINST 22%

FOR: 38,137,068AGAINST: 10,979,123

BICYCLE THERAPEUTICS PLC’s own tally for this item (“Proposal 9: To approve an amendment to the Company's Amended and Restated 2020 Equity Incentive Plan, which amendment is set forth in the Company's definitive proxy statement.”): 38,137,068 for, 10,979,123 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,202,355 outstanding shares: 55% for, 16% against (71% of the company cast a for/against vote).

The 23 asset managers below cast 5% of the shares they voted on this item FOR (149,250 for, 3,010,946 against).

AGAINST 95%

FOR: 149,250 (4.7%)AGAINST: 3,010,946 (95.3%)

Largest asset managers voting on “To approve an amendment to our Amended and Restated 2020 Equity Incentive Plan, which amendment is set forth a” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	0	1,231,314	Against
HARBOR FUNDS	0	1,000,820	Against
Principal	0	293,300	Against
Harbor Funds II	149,250	0	For
BlackRock	0	144,207	Against
Goldman Sachs	0	100,250	Against
Morgan Stanley	0	58,724	Against
State Street	0	31,423	Against
John Hancock	0	25,602	Against
OLD WESTBURY FUNDS INC	0	25,352	Against
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	0	21,900	Against
Harbor ETF Trust	0	16,482	Against
Listed Funds Trust	0	14,396	Against
ETF Series Solutions	0	12,764	Against
STEWARD FUNDS, INC.	0	11,209	Against
Equitable	0	11,014	Against
Mercer Funds	0	5,511	Against
ETFis Series Trust I	0	4,131	Against
ProShares	0	1,779	Against
Blackstone Alternative Investment Funds	0	300	Against
Fidelity	0	277	Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC	0	146	Against
CITY NATIONAL ROCHDALE FUNDS	0	45	Against

4. To authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the year ending December 31, 2025.

AUDIT-RELATEDCOMPENSATIONMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 49,116,858AGAINST: 17,701

BICYCLE THERAPEUTICS PLC’s own tally for this item (“Proposal 6: To authorize the Audit Committee of the Company's Board of Directors (the "Board") to determine the Company's U.K”): 49,116,858 for, 17,701 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,202,355 outstanding shares: 71% for, 0.1% against (71% of the company cast a for/against vote).

The 22 asset managers below cast 100% of the shares they voted on this item FOR (3,160,050 for, 0 against).

FOR 100%

FOR: 3,160,050 (100.0%)

Largest asset managers voting on “To authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the year ending De” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Vote
T. Rowe Price	1,231,314	For
HARBOR FUNDS	1,000,820	For
Principal	293,300	For
Harbor Funds II	149,250	For
BlackRock	144,207	For
Goldman Sachs	100,250	For
Morgan Stanley	58,724	For
State Street	31,423	For
John Hancock	25,602	For
OLD WESTBURY FUNDS INC	25,352	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	21,900	For
Harbor ETF Trust	16,482	For
Listed Funds Trust	14,396	For
ETF Series Solutions	12,764	For
STEWARD FUNDS, INC.	11,209	For
Equitable	11,014	For
Mercer Funds	5,511	For
ETFis Series Trust I	4,131	For
ProShares	1,779	For
Blackstone Alternative Investment Funds	300	For
Fidelity	277	For
CITY NATIONAL ROCHDALE FUNDS	45	For

5. To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2025.

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 22 asset managers below cast 100% of the shares they voted on this item FOR (3,160,050 for, 0 against).

FOR: 3,160,050 (100.0%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the l” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Vote
T. Rowe Price	1,231,314	For
HARBOR FUNDS	1,000,820	For
Principal	293,300	For
Harbor Funds II	149,250	For
BlackRock	144,207	For
Goldman Sachs	100,250	For
Morgan Stanley	58,724	For
State Street	31,423	For
John Hancock	25,602	For
OLD WESTBURY FUNDS INC	25,352	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	21,900	For
Harbor ETF Trust	16,482	For
Listed Funds Trust	14,396	For
ETF Series Solutions	12,764	For
STEWARD FUNDS, INC.	11,209	For
Equitable	11,014	For
Mercer Funds	5,511	For
ETFis Series Trust I	4,131	For
ProShares	1,779	For
Blackstone Alternative Investment Funds	300	For
Fidelity	277	For
CITY NATIONAL ROCHDALE FUNDS	45	For

6. To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 49,094,477AGAINST: 40,022

BICYCLE THERAPEUTICS PLC’s own tally for this item (“Proposal 5: To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.K”): 49,094,477 for, 40,022 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,202,355 outstanding shares: 71% for, 0.1% against (71% of the company cast a for/against vote).

The 22 asset managers below cast 100% of the shares they voted on this item FOR (3,160,050 for, 0 against).

FOR 100%

FOR: 3,160,050 (100.0%)

Largest asset managers voting on “To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England,” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Vote
T. Rowe Price	1,231,314	For
HARBOR FUNDS	1,000,820	For
Principal	293,300	For
Harbor Funds II	149,250	For
BlackRock	144,207	For
Goldman Sachs	100,250	For
Morgan Stanley	58,724	For
State Street	31,423	For
John Hancock	25,602	For
OLD WESTBURY FUNDS INC	25,352	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	21,900	For
Harbor ETF Trust	16,482	For
Listed Funds Trust	14,396	For
ETF Series Solutions	12,764	For
STEWARD FUNDS, INC.	11,209	For
Equitable	11,014	For
Mercer Funds	5,511	For
ETFis Series Trust I	4,131	For
ProShares	1,779	For
Blackstone Alternative Investment Funds	300	For
Fidelity	277	For
CITY NATIONAL ROCHDALE FUNDS	45	For

7. To re-elect Alessandro Riva as a director, who retires in accordance with the Articles of Association.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 40,034,345AGAINST: 9,086,349

BICYCLE THERAPEUTICS PLC’s own tally for this item (“Proposal 1: To re-elect as a director Alessandro Riva.”): 40,034,345 for, 9,086,349 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,202,355 outstanding shares: 58% for, 13% against (71% of the company cast a for/against vote).

The 22 asset managers below cast 47.8% of the shares they voted on this item FOR (1,509,646 for, 1,650,404 against).

FOR 47.8%AGAINST 52.2%

FOR: 1,509,646 (47.8%)AGAINST: 1,650,404 (52.2%)

Largest asset managers voting on “To re-elect Alessandro Riva as a director, who retires in accordance with the Articles of Association.” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	1,231,314	0	For
HARBOR FUNDS	0	1,000,820	Against
Principal	0	293,300	Against
Harbor Funds II	149,250	0	For
BlackRock	91,153	53,054	For
Goldman Sachs	0	100,250	Against
Morgan Stanley	0	58,724	Against
State Street	1,268	30,155	Against
John Hancock	25,602	0	For
OLD WESTBURY FUNDS INC	0	25,352	Against
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	0	21,900	Against
Harbor ETF Trust	0	16,482	Against
Listed Funds Trust	0	14,396	Against
ETF Series Solutions	0	12,764	Against
STEWARD FUNDS, INC.	0	11,209	Against
Equitable	11,014	0	For
Mercer Funds	0	5,511	Against
ETFis Series Trust I	0	4,131	Against
ProShares	0	1,779	Against
Blackstone Alternative Investment Funds	0	300	Against
Fidelity	0	277	Against
CITY NATIONAL ROCHDALE FUNDS	45	0	For

8. To re-elect Stephen Sands as a director, who retires in accordance with the Articles of Association.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 47,652,747AGAINST: 1,481,237

BICYCLE THERAPEUTICS PLC’s own tally for this item (“Proposal 2: To re-elect as a director Stephen Sands.”): 47,652,747 for, 1,481,237 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,202,355 outstanding shares: 69% for, 2% against (71% of the company cast a for/against vote).

The 22 asset managers below cast 97% of the shares they voted on this item FOR (3,067,629 for, 92,421 against).

FOR 97%

FOR: 3,067,629 (97.1%)AGAINST: 92,421 (2.9%)

Largest asset managers voting on “To re-elect Stephen Sands as a director, who retires in accordance with the Articles of Association.” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	1,231,314	0	For
HARBOR FUNDS	1,000,820	0	For
Principal	293,300	0	For
Harbor Funds II	149,250	0	For
BlackRock	53,054	91,153	Against
Goldman Sachs	100,250	0	For
Morgan Stanley	58,724	0	For
State Street	30,155	1,268	For
John Hancock	25,602	0	For
OLD WESTBURY FUNDS INC	25,352	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	21,900	0	For
Harbor ETF Trust	16,482	0	For
Listed Funds Trust	14,396	0	For
ETF Series Solutions	12,764	0	For
STEWARD FUNDS, INC.	11,209	0	For
Equitable	11,014	0	For
Mercer Funds	5,511	0	For
ETFis Series Trust I	4,131	0	For
ProShares	1,779	0	For
Blackstone Alternative Investment Funds	300	0	For
Fidelity	277	0	For
CITY NATIONAL ROCHDALE FUNDS	45	0	For

9. To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2024 (the "2024 U.K. Annual Report").

CORPORATE GOVERNANCEMajority of the votes cast: yes

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 49,001,464AGAINST: 133,090

BICYCLE THERAPEUTICS PLC’s own tally for this item (“Proposal 7: To receive and adopt the Company's U.K”): 49,001,464 for, 133,090 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,202,355 outstanding shares: 71% for, 0.2% against (71% of the company cast a for/against vote).

The 22 asset managers below cast 100% of the shares they voted on this item FOR (3,160,050 for, 0 against).

FOR 100%

FOR: 3,160,050 (100.0%)

Largest asset managers voting on “To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2024 (the ” at BICYCLE THERAPEUTICS PLC, 2024-2025
Asset manager	For	Vote
T. Rowe Price	1,231,314	For
HARBOR FUNDS	1,000,820	For
Principal	293,300	For
Harbor Funds II	149,250	For
BlackRock	144,207	For
Goldman Sachs	100,250	For
Morgan Stanley	58,724	For
State Street	31,423	For
John Hancock	25,602	For
OLD WESTBURY FUNDS INC	25,352	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	21,900	For
Harbor ETF Trust	16,482	For
Listed Funds Trust	14,396	For
ETF Series Solutions	12,764	For
STEWARD FUNDS, INC.	11,209	For
Equitable	11,014	For
Mercer Funds	5,511	For
ETFis Series Trust I	4,131	For
ProShares	1,779	For
Blackstone Alternative Investment Funds	300	For
Fidelity	277	For
CITY NATIONAL ROCHDALE FUNDS	45	For

Largest BICYCLE THERAPEUTICS PLC shareholders voting in 2024-2025

Ranked by the number of BICYCLE THERAPEUTICS PLC shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 69,202,355 shares outstanding at the time of that meeting.

Top BICYCLE THERAPEUTICS PLC shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BAKER BROS. ADVISORS LP	15.73%
2	FCPM III SERVICES B.V.	4.99%
3	Point72	4.76%
4	T. Rowe Price	3.99%
5	ARMISTICE CAPITAL, LLC	3.12%
6	WESTFIELD CAPITAL MANAGEMENT CO LP	3.05%
7	Siren, L.L.C.	2.24%
8	BNP Paribas Asset Management Holding S.A.	1.52%
9	HARBOR FUNDS	1.45%
10	EcoR1 Capital, LLC	1.31%

Reported BICYCLE THERAPEUTICS PLC ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BICYCLE THERAPEUTICS PLC beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Point72	5.34%	13F
Armistice Capital, LLC	4.91%	13G
LONG FOCUS CAPITAL MANAGEMENT, LLC	4.78%	13G
Raymond Debbane	2.26%	13G
T. Rowe Price	2.22%	13F
Morgan Stanley	1.44%	13F
BlackRock	0.47%	13F
Renaissance Technologies	0.44%	13F
Citadel Advisors	0.24%	13F
State Street	0.12%	13F

Percentages above are of 69,202,355 shares outstanding, as reported by BICYCLE THERAPEUTICS PLC on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BICYCLE THERAPEUTICS PLC’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At BICYCLE THERAPEUTICS PLC's shareholder meeting held 2025-06-17, in the 2024-2025 proxy season, 108 asset managers reported how they voted in their SEC Form N-PX filings, covering 364 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: BICYCLE THERAPEUTICS PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-17.

BICYCLE THERAPEUTICS PLC proxy season coverage: 2023-2024 · 2024-2025 (this page).